Skip to content
Subscriber Only

Immucor to Be Acquired by TPG Capital for $1.97 Billion

Immucor Inc., the leading maker of tests to screen blood before transfusions, agreed to sell itself to private-equity firm TPG Capital for $1.97 billion.

The offer of $27 a share is 30 percent more than Immucor’s closing price on July 1, the last trading day before the deal was announced, the Norcross, Georgia-based company said in a statement today. Immucor said that under the agreement it may solicit higher bids from other suitors through Aug. 15.